Latest Advances in Lung Cancer Research

For many years, small cell lung cancer treatments stayed mostly the same. Chemotherapy was the main option, and immunotherapy added in 2018 only helped a little. But now, new therapies are bringing real hope to patients and their families.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

Drs. Riely and Levy explain the necessity of reflex genomic testing in lung cancer to ensure personalized treatment and better patient outcomes.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

Dr. Ross Camidge shares clinical insights and personal reflections on the evolution of lung cancer research and the vital importance of innovation in targeted therapies.

Small cell lung cancer (SCLC) is one of the deadliest forms of lung cancer. It makes up about 15% of all lung cancer cases and has a 5-year survival rate of only 7%. While newer treatments like immunotherapy have helped some patients, most still see only small benefits. New small cell lung cancer research published in Nature Communications may help change that.

Mayo Clinic researchers found genetic and cellular clues, including missing a gene and “zombie cells”, that help explain why some lung tumors respond well to immunotherapy.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

French study finds chemotherapy after lung cancer surgery shows unclear benefits for patients over 75, requiring careful patient selection.

Immunotherapy is transforming small cell lung cancer treatment, improving survival in both early and advanced stages, with new drugs offering long-term disease control.

Tarlatamab extends survival and reduces side effects for small cell lung cancer patients, emerging as a promising new second-line treatment option.